Introduction {#sec1}
============

Discussions of "big data" are on the forefront of researchers' minds in almost every discipline. However, in the biomedical sciences, the growth of biological data is unprecedented, with new data being created more quickly than it can be efficiently organized^[@r1-2835924]^. Automating large-scale, cross-domain heterogeneous data aggregation across many different sites continues to pose a major challenge for bioinformaticians. Several groups, including the U.S. National Center for Biomedical Ontology (NCBO), have aimed to standardize data via the usage of normalized ontologies and nomenclatures^[@r1-2835924]^. It is important to note that these controlled vocabularies are sometimes difficult to map to or from, due, in part, to looming digital dark ages, referring to difficulties in understanding various file formats and identifier types after their deprecation^[@r1-2835924]^. Having a "universal" identifier for biological concepts continues to be a challenge. This problem is further compounded as new databases or meta-databases (e.g. comprehensive databases) are constructed. These efforts often end up introducing new identifiers for existing concepts. Further, the status quo as far as advanced biological databases are concerned seems to be locally downloading databases or simply copying them to other servers. This results not only in duplicate data, but also in a data source which can quickly become out-of-date. A potential solution to these concerns, discussed herein, is the usage of application programming interfaces (APIs). These systems abstract database implementations, making input and output data easier to query, consume, and analyze in a standardized manner ([Fig 1.](#f1-2835924){ref-type="fig"})

Many biological databases have open APIs, such as Ensembl, UniProt, PubMed, and KEGG, while others are semi-open, requiring registration and some kind of security key (such as UMLS or Open PHACTS)^[@r4-2835924],[@r5-2835924],[@r6-2835924],[@r7-2835924]^. Since APIs are tied directly to their component databases, they are as up to date as possible. In addition, minimal data are pulled to the local machine when queried, mitigating the copying of large databases.

Our system, labeled *GNOMICS* (Genomic Nomenclature Omnibus and Multifaceted Informatics and Computational Suite) is a grouping of API-based Python programs organized into objects which can be extended or scaled as needed. In addition to the command-line interface, a beta front-end is also available, having been built primarily using Electron and AngularJS.

Methods {#sec2}
=======

The *GNOMICS* system was built upon user-friendly and understandable objects, of which there are currently 25 ([Table 1](#t1-2835924){ref-type="table"}). While these modules and others are still under development, they allow for a diverse array of functions, including *arterial supply* for anatomical structures, *effective time* for drugs, *metabolic rate* for taxa, and *effective rotor count* for compounds, among others.

Additionally, a twenty-sixth User object is available. This object stores information about the eleven API systems that require a separate user API key for usage (ChemSpider, DPLA, Elsevier, EOL, FDA, ISBNdb, NCBO, OMIM, OpenPHACTS, Springer, and UMLS)^[@r1-2835924],[@r1-2835924],[@r1-2835924],[@r1-2835924],[@r1-2835924],[@r1-2835924]^. Currently 35 API systems are available, ranging from UniProt to Ensembl to Wikipedia. Lastly, 51 Python 3 packages were adapted for *GNOMICS* use, including BeautifulSoup, Bio, BioPython, Bioservices, the ChEMBL Webresource Client, ChemSpiPy, GEOparse, Intermine, LibChEBIpy, MyGene, MyVariant, NLTK, PubChemPy, and PyTaxize^[@r1-2835924],[@r1-2835924],[@r1-2835924],[@r1-2835924],[@r1-2835924],[@r1-2835924],[@r1-2835924]^. The inclusion of these packages prevented unnecessary code duplication.

Each component object has several subfolders whose functions relate to parsing specific materials returned from component APIs for command-line usage, allowing for simpler functions such as identifier conversion. *Interaction objects*, which allow for relating an object to another object or series of objects, are paramount to the success of *GNOMICS* ([Fig. 2](#f1-2835924){ref-type="fig"}). For example, a gene can be related to several other genes via orthology; a disease can be related to a particular anatomical structure if it occurs there; or a drug can berelated to adverse events (AEs) through drug-compound interactions. 63 such interaction objects are available or under development.

In addition, there are areas for locally downloading data to facilitate faster querying time (as well as allowing for integration of databases without programmatic access) and an area for documentation. Allowing for different import and export formats is crucial as well, with CSV, TSV, XML, HTML, JSON, JSONP, and YAML appearing as the most commonly parsed formats, alongside biological formatting standards such as BED and FASTA. Accessory are preformatted reports summarizing data in PDF, Microsoft Word, Microsoft Excel, CSV, and TSV files.

Results {#sec3}
=======

268 object-specific identifiers were included in *GNOMICS* with various mappings originating from the Ontology Lookup Service (OLS) at EMBL-EBI, the National Center for Biomedical Ontology (NCBO) BioPortal, the UMLS Metathesaurus, Wikidata, and others^[@r1-2835924],[@r1-2835924],[@r1-2835924]^. These mappings may be one-to-one or one-to-many. The Human Disease Ontology (DOID) for heart disease, for example, maps to 6 SNOMED-CT U.S. IDs in OLS and NCBO, but only to one UMLS CUI in both sources^[@r1-2835924][@r1-2835924],[@r1-2835924]^ Non-object-specific identifiers (such as MedDRA, SNOMED-CT, or MeSH) must be mapped to an object-specific identifier before inclusion with that specific id^[@r1-2835924][@r1-2835924],[@r1-2835924][@r1-2835924],[@r1-2835924]^. Including non-object-specific identifiers, 533 identifier types are available among the 25 object types. Many identifiers appear in multiple sources allowing for mapping if a single source is under maintenance or briefly unavailable for other reasons (on average, each identifier is available from three sources).

Included with identifiers are terms and labels provided by the various sources, as well as accepted synonyms and translations. 76 languages are available due to integration of translatable terms from MeSH, MedDRA, CPT, LOINC, and Wikipedia.

First, a few test searches were run for all objects with available search functionality ("breast cancer," "SLC4A1," "ibuprofen", etc.). Each test was run five times across the 17 such objects, with all component databases and ontologies returning results in an average 0.160864599 seconds (*s* = 0.01142). Next, we timed 45 randomly chosen interaction object search functions using the same methodology. These returned results in an average 0.007318 seconds (*s* = 0.00525). Artificially crippling single APIs with repeated data (such as disallowing access to the OLS domain) was met with no significant change in speed, as most identifiers and search results could be found on multiple platforms. This, however, is not currently the case for PubMed or Ensembl, among others.

Two more additional complex tests looked at synthesizing phenotypes related to adverse events caused by a drug and phenotypes related to the disease that drug is used to treat, as well as normal gene expression for genes known to interact with a given drug in certain tissues alongside AE counts endemic to those same tissues^[@r1-2835924],[@r1-2835924],[@r1-2835924],[@r1-2835924]^. The first test found 200 phenotypes associated with amiodarone usage and 20 phenotypes observed in the adverse event (AE) cardiac arrhythmia. There were 14 overlapping phenotypes discovered, including bradycardia, congestive heart failure, cardiac arrest, and ventricular tachycardia; all of which are common side effects of amiodarone. The second test involved looking at amiodarone AE counts and mapping those events to tissues; next we found drug/gene interactions for amiodarone and found normal expression levels for those genes in the same tissues ([Figure 3](#f1-2835924){ref-type="fig"}).

Following this, extensibility was tested by adapting PubTator and NOBLE Coder into *GNOMICS*, allowing for programmatic annotation of free text. The NLTK package was added to supplement these programs as well^[@r1-2835924],[@r1-2835924]^.

Discussion {#sec4}
==========

Cross-domain integration and comparison of large volumes of information across clinical and translational research applications continues to be a major challenge in the biomedical domain. With both a programmatic and visual interface, as well as a focus on terminology translation, we anticipate that *GNOMICS* and its continued development could accelerate the process of bringing together the two disparate fields. Additionally, *GNOMICS* has an intuitive object-based usage that can be understood quickly, keeping the relative startup cost smaller than that of a dedicated database download. The system manages to deliver uniform data which can be easily manipulated and parsed as the user finds necessary. *GNOMICS* further remains continually up-to-date given its connectedness with its component sources and continues to be a portable and scalable solution in the biomedical data landscape. However, *GNOMICS* has certain limitations. Because it is based on web services, *GNOMICS* requires a dedicated internet connection and more substantial API limits. While several biomedical and genomics databases have open API systems, others require registration and complex layers of security tokens and request tickets. While *GNOMICS* does some of the heavy lifting in these situations, users still have to navigate some of these processes manually. Further, for what *GNOMICS* gains in portability, it loses in speed, as certain databases may take longer to respond to queries. However, it has been shown that given increases in processing power, this tradeoff is often negligible to the end-user.

Conclusion {#sec5}
==========

*GNOMICS* is under continuous development, including addition of more object types, functions, and identifier mappings. Currently, the *GNOMICS* system is biased towards well-established and/or heavily trafficked databases, especially those with APIs. Additional multi-system testing is ongoing, with the front-end interface still in active development. This includes taking into account portability- and scalability-related issues alongside those components of the command-line interface. To address these points and others, a public GitHub source [(<https://github.com/Superraptor/gnomics>)]{.ul} is available with a README and Wiki. Documentation is provided which offers insight into identifier types available, database coverage, and language coverage, among other things. Additions to and recommendations for the system are highly encouraged, with plugins written in Python or other programming languages easily adaptable into the existing framework.

![Example outlining data flow to/from a client to an application via an API.](2835924f1){#f1-2835924}

![Example workflow for user query for a gene/compound interaction. Blue arrows signify data calls, whereas yellow arrows signify the returned data pipeline. Only individual gene API calls are expanded for emphasis.](2835924f2){#f2-2835924}

![Example output showcasing amiodarone's observed AEs mapped to tissues, alongside normal gene expression for known drug-gene interactions in amiodarone. Note the large number of AEs mapped to bronchiole and the relatively high expression of *SFTPA1* in bronchiole. Further, *SFTPA1* polymorphisms have been noted as influencing susceptibility to pulmonary fibrosis and pulmonary toxicity is one of the most serious AEs related to amiodarone usage^[@r27-2835924],[@r25-2835924]^.](2835924f3){#f3-2835924}

###### 

*GNOMICS* objects breakdown. Showcased are the approximate number of available records, number of identifiers currently available, and the number of properties included in the object. Please note that not all sources have published exact numbers of available objects.

  Object                 \# Records      \# Identifiers   \# Properties
  ---------------------- --------------- ---------------- ---------------
  Adverse Event          30,126          7                0
  Anatomical Structure   526,706         39               8
  Assay                  1,267,241       4                14
  Biological Process     26,678          1                0
  Cell Line              125,369         4                0
  Cellular Component     4,150           1                0
  Clinical Trial         619,701         5                24
  Compound               332,518,372     23               55
  Disease                382,830         28               11
  Drug                   1,541,646       34               21
  Gene                   45,569,934      21               16
  Genotype               1,069           1                0
  Molecular Function     11,134          2                0
  Patent                 4,000,000       3                0
  Pathway                2,010,623       5                10
  People                 26,759,399      1                0
  Phenotype              358,575         19               0
  Procedure              397,186         8                0
  Protein                586,444,112     15               9
  Reference              477,357,444     20               13
  Symptom                3,129           3                0
  Taxa                   6,739,136       11               98
  Tissue                 17,520          6                0
  Transcript             202,338         2                0
  Variation              801,208,836     5                0
  Total:                 2,288,123,254   268              279
